HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

Executive Summary

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

You may also be interested in...

EWG Sunscreen Assessment Finds Oxybenzone Use Slowing, But Shows Most Still Are ‘Inadequate’

Environmental Working Group’s annual “‘Guide to Sunscreens” finds 30% of non-mineral sunscreen products contain controversial ingredient oxybenzone, down from 40% last year and 60% three years ago.

On EU's Heels, UK Seeks Data On UV Filters Suspected Of Endocrine Disruption

The Cosmetic, Toiletry and Perfumery Association hopes to leverage data submitted for the UK evaluation to defend oxybenzone, homosalate, octocrylene and other ingredients in the EU, partnering with Cosmetics Europe.

Cosmetic Brands, And Animals, Have Growing Problem In Europe; Commission’s Nanomaterials Report

The European Commission’s Scientific Committee for Consumer Safety has been unable to get the data it needs to properly assess the safety of nanomaterials in cosmetic products. The European Commission expects REACH to address the issue, and that is probably not a prospect that industry stakeholders relish.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts